YM BioSciences Announces Preclinical Data Confirming Nimotuzumab,Binds to the EGF Receptor and Potentiates Radiotherapy ( onal antibody that targets the epiderma...)

YM BioSciences Announces Preclinical Data Confirming Nimotuzumab,Binds to the EGF Receptor and Potentiates Radiotherapy

onal antibody that targets the epidermal growth factor receptor (EGFR) and is approved in several countries for treatment of various types of head and neck cancer; and AeroLEF(TM), a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl in development for the treatment of moderate to severe pain, including cancer pain.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that AeroLEF(TM) will continue to generate positive efficacy and safety data in future clinical trials; and that YM and its various partners will complete their respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT: Enquiries: Thomas Fechtner, the Trout Group LLC, Tel. (212)477-9007 x31, Fax (212) 460-9028, Email: ; JamesSmith, the Equicom Group Inc., Tel. (416) 815-0700 x 229, Fax (416)815-0080, Email: '"/>

Page: 1 2 3 4
Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
3. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
4. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
5. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
6. ImmuneRegen BioSciences Announces Promising Data on Homspera Suggesting Potential as a Co-Therapeutic Agent
7. Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein
8. IR BioSciences Announces Data Demonstrating Radilex Stimulation of Stem Cells Results in Hematopoietic Recovery Following Lethal Irradiation
9. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
10. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis

Post Your Comments:

(Date:8/14/2008)...a., Aug. 14 /- The Clinical Trials,Bo...ucating physicians,clinical coordinators, clinica...l trial. It will be held in Boca Raton at the Boca...ators, clinical coordinators, monitors and,other i...ow to incorporate,clinical trials into a practice,...

(Date:8/14/2008)...pment to begin in late 2008 or in early 2009 -, S...-- Nuvelo, Inc.,(Nasdaq: NUVO ) today announced p... trial of NU172, demonstrating that the direct thr...ticoagulation with a rapid,return toward baseline ...rofile., "NU172 has the potential to address many...

(Date:8/13/2008)...RNewswire-FirstCall/ -- As biotechnology,pharmace...ove clinical,trials beyond their own borders to ot...pe and South America, complicated regulatory envir...ess, according to an analysis by,Aon Corporation (...provides,those companies a visual representation o...

(Date:8/13/2008)...hid Pharma partners with Diakron, MORRIS PLAINS, ...als,Inc. announced today the signing of an exclus...oral anticoagulant drug candidate discovered and,d...& Co. Inc. Under the,terms of the agreement, Diakr...proved, market and distribute the compound worldwi...

Breaking Medicine Technology:Nuvelo Announces Positive Phase 1b Proof-of-Concept Data With Anticoagulant NU172 2 Nuvelo Announces Positive Phase 1b Proof-of-Concept Data With Anticoagulant NU172 3 Nuvelo Announces Positive Phase 1b Proof-of-Concept Data With Anticoagulant NU172 4 Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders 2 Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders 3 Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders 4 Diakron Licenses Anticoagulant Drug Candidate from Merck & Co., Inc. 2 Phase 3 studies show golimumab significantly improved signs and symptoms of rheumatoid arthritis 5926 1 Phase 3 studies show golimumab significantly improved signs and symptoms of rheumatoid arthritis 5926 2 Phase 3 studies show golimumab significantly improved signs and symptoms of rheumatoid arthritis 5926 3 Phase 3 studies show golimumab significantly improved signs and symptoms of rheumatoid arthritis 5926 4 Eleven Going on 70 3A SCAN Health Plan Helps Fifth Graders Understand Aging Through First Ever Senior Sensitivity Training for Kids 21542 1 Eleven Going on 70 3A SCAN Health Plan Helps Fifth Graders Understand Aging Through First Ever Senior Sensitivity Training for Kids 21542 2 Tubbs Jones Addresses Health Disparities Issue During Hearing 21537 1 Tubbs Jones Addresses Health Disparities Issue During Hearing 21537 2 Three peat 3A Nurture 28R 29 Strikes Gold Again at NeoCon 21535 1 Three peat 3A Nurture 28R 29 Strikes Gold Again at NeoCon 21535 2

[0] Clinical Trials Bootcamp Announces Inaugural Meeting [0] Nuvelo Announces Positive Phase 1b Proof-of-Concept Data With Anticoagulant NU172 [0] Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders [0] Diakron Licenses Anticoagulant Drug Candidate from Merck & Co., Inc.

... Merck,Serono S.A. (virt-x: SEO) announced today t...hase III development for the treatment,of Parkinso...essor,Fabrizio Stocchi at the American Academy of ...etts, USA. These data are from a,6-month (24 weeks...nternational trial. , "These data are promising fo...

...ational Cancer,Institute , , , , , , BAS... today in,the Journal of the National Cancer Insti...n to improve overall survival in patients,with lym...1 The,review further stated that the improvement i... with mantle cell lymphoma, a rare,aggressive for...

Other Medicine Technology:Phase III Data on Safinamide in Parkinson’s Disease Presented,at American Academy of Neurology 59th Annual Meeting 2 Phase III Data on Safinamide in Parkinson’s Disease Presented,at American Academy of Neurology 59th Annual Meeting 3 Phase III Data on Safinamide in Parkinson’s Disease Presented,at American Academy of Neurology 59th Annual Meeting 4 Phase III Data on Safinamide in Parkinson’s Disease Presented,at American Academy of Neurology 59th Annual Meeting 5 MabThera Significantly Increases Survival of Lymphoma Patients,Regardless of Chemotherapy Regimen 2 MabThera Significantly Increases Survival of Lymphoma Patients,Regardless of Chemotherapy Regimen 3 MabThera Significantly Increases Survival of Lymphoma Patients,Regardless of Chemotherapy Regimen 4

Phase III Data on Safinamide in Parkinson’s Disease Presented,at American Academy of Neurology 59th Annual Meeting MabThera Significantly Increases Survival of Lymphoma Patients,Regardless of Chemotherapy Regimen

(Date:8/20/2008)...r-old Contestant Wins Trip to Little League Baseba... The National Spit Tobacco Education,Program (NSTE...st today,and encouraged young baseball players to...ddiction and the health risks of using tobacco pro...year,s slogan contest winner is,Joe Reck, a nine-y...

(Date:8/20/2008)...cently enacted Medicare Improvement Law immediatel...re Advantage insurance companies .../PRNewswire/ -- When the House and Senate,overrode...gislation,protecting Medicare beneficiaries, they ...e Advantage plans during one of the busiest months...

(Date:8/20/2008)...T CREEK, Calif., Aug. 20 /PRNewswire-FirstCall/ --... reported preliminary income from,continuing opera...f $27.5,million, or $0.76 per diluted share, inclu...er diluted share, related to provisions for store,... a 6.8 percent increase,compared with income from ...

(Date:8/20/2008)...FIELD, Mich., Aug. 20 /PRNewswire/ -- WXYZ- TV/Cha...llness Promotion will give thousands of,Detroit me...ALTHY LIVING,FOR KIDS" program. This year the prog....m. to 5 p.m. at the Charles H. Wright Museum of A...77, "Healthy Living for Kids",has provided free im...

[0] Slogan Contest Educates Young Baseball Players About the Dangers of Tobacco Use [0] Medicare Advantage Plans Struggle to Comply With New Federal Law [0] Longs Drug Stores Corporation Reports Second Quarter Results [0] WXYZ-TV/Channel 7 is 'On Your Side' With Healthy Living For Kids; Free Immunizations for Children on Sunday, August 24 at Charles H. Wright Museum of African American History

...is (IPF) is a disease whose cause and cure are not...it till date//. It is a lung disease characterized...w deterioration of the entire organ (lung). Stati...cans suffer from the disease and 31000 new cases a...

...s Secretary Michael Leavitt said that his country ... bird flu virus is yet to be detected in North Ame...me before it crosses the Atlantic after spreading ...ica. While it was impossible to predict the flu'...

...rch, more than 200,000 miners in Rajasthan suffer ... caused by the inhalation// of dust containing cry...ajasthan, according to figures by the National Com...miners work in mines containing silica dust and ar...

...st has been severely handicapped by the multiple s...l over a decade//. After British doctors told her...r her she took a loan of over ?12,000 to go to the...njection, a procedure that is unlicensed in the UK...

Other Medicine News:Health News:Lesser Know Facts about Idiopathic Pulmonary Fibrosis (IPF) 2 Health News:More Than 200,000 Miners In Rajasthan Suffer From Silicosis 2 Health News:Multiple Sclerosis Patient Seeks Help of Stem Cells 2

Lesser Know Facts about Idiopathic Pulmonary Fibrosis (IPF)US Not Ready To Face The Bird Flu Outbreak More Than 200,000 Miners In Rajasthan Suffer From Silicosis Multiple Sclerosis Patient Seeks Help of Stem Cells

...RUP Laboratories is a national reference laborator...research and development. ARUP offers an extensive...sts in clinical and anatomic pathology. Owned by t...include more than half of the nation's university ...

Medicine Products:

Rapid Plasma Reagin (RPR with Reflex to Fluorescent Treponemal Antibody, IgG Confirmation Rapamune Raji Cell Immune Complex Assay RA

( onal antibody that targets the epiderma...)YM BioSciences Announces Preclinical Data Confirming Nimotuzumab,Binds to the EGF Receptor and Potentiates Radiotherapy,Health